Amgen CEO Bob Bradway told CNBC's Jim Cramer about his company's treatment to reduce heart attack risk.
Monday - Friday, 6:00 - 7:00 PM ET
In this article
Amgen
CEO Bob Bradway detailed promising results from the company’s recent drug trial, telling CNBC’s Jim Cramer that the medicine can reduce the risk of heart attack.
“This trial answered questions that have been on the mind of investigators and physicians and patients for some time,” Bradway said.
Amgen CEO Bob Bradway discussed his company's weight loss drug in an interview with CNBC's Jim Cramer.
Go behind the scenes with Jim Cramer and Jeff Marks of the CNBC Investing Club as they talk candidly about the market's biggest…
Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the next…
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
